1. Home
  2. AVXL vs PACB Comparison

AVXL vs PACB Comparison

Compare AVXL & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVXL
  • PACB
  • Stock Information
  • Founded
  • AVXL 2004
  • PACB 2000
  • Country
  • AVXL United States
  • PACB United States
  • Employees
  • AVXL N/A
  • PACB N/A
  • Industry
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • PACB Biotechnology: Laboratory Analytical Instruments
  • Sector
  • AVXL Health Care
  • PACB Industrials
  • Exchange
  • AVXL Nasdaq
  • PACB Nasdaq
  • Market Cap
  • AVXL 484.2M
  • PACB 452.1M
  • IPO Year
  • AVXL N/A
  • PACB 2010
  • Fundamental
  • Price
  • AVXL $7.45
  • PACB $1.60
  • Analyst Decision
  • AVXL Strong Buy
  • PACB Buy
  • Analyst Count
  • AVXL 2
  • PACB 15
  • Target Price
  • AVXL $43.00
  • PACB $2.92
  • AVG Volume (30 Days)
  • AVXL 1.6M
  • PACB 11.4M
  • Earning Date
  • AVXL 11-25-2024
  • PACB 11-07-2024
  • Dividend Yield
  • AVXL N/A
  • PACB N/A
  • EPS Growth
  • AVXL N/A
  • PACB N/A
  • EPS
  • AVXL N/A
  • PACB N/A
  • Revenue
  • AVXL N/A
  • PACB $173,147,000.00
  • Revenue This Year
  • AVXL N/A
  • PACB N/A
  • Revenue Next Year
  • AVXL N/A
  • PACB $25.88
  • P/E Ratio
  • AVXL N/A
  • PACB N/A
  • Revenue Growth
  • AVXL N/A
  • PACB 2.14
  • 52 Week Low
  • AVXL $3.25
  • PACB $1.16
  • 52 Week High
  • AVXL $10.45
  • PACB $10.65
  • Technical
  • Relative Strength Index (RSI)
  • AVXL 54.68
  • PACB 36.99
  • Support Level
  • AVXL $7.55
  • PACB $1.82
  • Resistance Level
  • AVXL $10.45
  • PACB $2.66
  • Average True Range (ATR)
  • AVXL 0.84
  • PACB 0.34
  • MACD
  • AVXL 0.08
  • PACB -0.08
  • Stochastic Oscillator
  • AVXL 37.77
  • PACB 3.02

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

About PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Share on Social Networks: